CRINETICS PHARMACEUTICALS INC (CRNX)
Health Care · NASDAQ
A commercial-stage endocrine pharmaceutical company with a first-in-class oral GPCR-targeted therapy for acromegaly and a deep pipeline of programs across multiple endocrine diseases.
What CRINETICS PHARMACEUTICALS INC does
Crinetics Pharmaceuticals is a pharmaceutical company developing novel therapies for endocrine diseases and endocrine-related tumors, with a core expertise in targeting GPCRs using small-molecule drugs. The company's lead product, PALSONIFY (paltusotine), was FDA-approved in September 2025 as the first once-daily oral somatostatin receptor ligand for acromegaly. Crinetics maintains a pipeline of 10+ programs targeting conditions including cushing's syndrome, neuroendocrine tumors, congenital adrenal hyperplasia, Graves' disease, and polycystic kidney disease.
Themes: ["Acromegaly treatment","Neuroendocrine tumors (NETs)","Congenital adrenal hyperplasia (CAH)","Cushing's syndrome","Graves' disease / Graves' orbitopathy","Endocrine-related oncology","GPCR-targeted small molecules","Obesity and metabolic disorders"]
Fundamentals
- Price$83.62 as of 2026-07-09 close
- Market cap$8.8B as of 2026-07-10
- 1-year return+158.6% as of 2026-07-09 close
- Net margin-2747.2% as of 2026-07-10
- Gross margin+86.0% as of 2026-07-10
- ROE-44.0% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+2277.5% as of 2026-07-10
- Beta0.16 as of 2026-07-10
Key risks (from latest filing)
[]
Competitors & peers
- Novartis (NVS) — Sandostatin (octreotide), lanreotide long-acting release for acromegaly and NETs
- Pfizer — Somavert (pegvisomant) for acromegaly
- Ipsen — Somatuline (lanreotide) for acromegaly and NETs
- Recordati — Signifor (pasireotide) for Cushing's syndrome
- Structure Therapeutics — oral somatostatin receptor agonist programs
- Viking Therapeutics — obesity and metabolic disease focus
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.